Statins reduce abdominal aortic aneurysm growth, rupture, and perioperative mortality: A systematic review and meta‐analysis

Journal of the American Heart Association

Volumn 7, Issue 19, 2018, Pages

  Salata, Konrad ^a,d   Syed, Muzammil ^e   Hussain, Mohamad A ^a,d   Mestral, Charles De ^a,d   Greco, Elisa ^a,d   Mamdani, Muhammad ^a,b,c,d,f   Tu, Jack V ^c,f,g,h   Forbes, Thomas L ^a,i   Bhatt, Deepak L ^j,k   Verma, Subodh ^a,d   Al Omran, Mohammed ^a,d,l  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h Canada   (Canada)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l KING SAUD UNIVERSITY   (Saudi Arabia)

more..

Author keywords

Aneurysm; Meta analysis; Rupture; Statin; Systematic review

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL AORTIC ANEURYSM; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; ENDOVASCULAR ANEURYSM REPAIR; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS; MORTALITY RATE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANEURYSM RUPTURE; DISEASE EXACERBATION; GLOBAL HEALTH; MORTALITY; PERIOPERATIVE PERIOD; PROCEDURES; SURVIVAL RATE; VASCULAR SURGERY;

ANEURYSM, RUPTURED; AORTIC ANEURYSM, ABDOMINAL; DISEASE PROGRESSION; GLOBAL HEALTH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERIOPERATIVE CARE; SURVIVAL RATE; VASCULAR SURGICAL PROCEDURES;

EID: 85052397295     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.008657     Document Type: Review

References (88)

1. Powell JT, Sweeting MJ, Brown LC, Gotensparre SM, Fowkes FG, Thompson SG. Systematic review and meta-analysis of growth rates of small abdominal aortic aneurysms. Br J Surg. 2011;98:609-618.
2. Schermerhorn ML, O’Malley AJ, Jhaveri A, Cotterill P, Pomposelli F, Landon BE. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. N Engl J Med. 2008;358:464-474.
3. Lee WA, Carter JW, Upchurch G, Seeger JM, Huber TS. Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001. J Vasc Surg. 2004;39:491-496.
4. Lifeline Registry of EPC. Lifeline registry of endovascular aneurysm repair: long-term primary outcome measures. J Vasc Surg. 2005;42:1-10.
5. van Marrewijk CJ, Leurs LJ, Vallabhaneni SR, Harris PL, Buth J, Laheij RJ; EUROSTAR Collaborators. Risk-adjusted outcome analysis of endovascular abdominal aortic aneurysm repair in a large population: how do stent-grafts compare? J Endovasc Ther. 2005;12:417-429.
6. Giles KA, Landon BE, Cotterill P, O’Malley AJ, Pomposelli FB, Schermerhorn ML. Thirty-day mortality and late survival with reinterventions and readmissions after open and endovascular aortic aneurysm repair in Medicare beneficiaries. J Vasc Surg. 2011;53:6-12, 13.e1.
7. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG; EVAR Trial Participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004;364:843-848.
8. Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, Buskens E, Grobbee DE, Blankensteijn JD; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2004;351:1607-1618.
9. Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM, Verhagen HJ, Buskens E, Grobbee DE; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2005;352:2398-2405.
10. Parent FN, Godziachvili V, Meier GH, Parker FM, Carter K, Gayle RG, Demasi RJ, Gregory RT. Endograft limb occlusion and stenosis after ANCURE endovascular abdominal aneurysm repair. J Vasc Surg. 2002;35:686-690.
11. Haider SE, Najjar SF, Cho JS, Rhee RY, Eskandari MK, Matsumura JS, Makaroun MS, Morasch MD. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original Excluder device. J Vasc Surg. 2006;44:694-700.
12. Criado FJ, Clark NS, McKendrick C, Longway J, Domer GS. Update on the Talent LPS AAA stent graft: results with “enhanced talent.” Semin Vasc Surg. 2003;16:158-165.
13. Najibi S, Steinberg J, Katzen BT, Zemel G, Lin PH, Weiss VJ, Lumsden AB, Chaikof EL. Detection of isolated hook fractures 36 months after implantation of the Ancure endograft: a cautionary note. J Vasc Surg. 2001;34:353-356.
14. Beebe HG, Cronenwett JL, Katzen BT, Brewster DC, Green RM; Vanguard Endograft Trial Investigators. Results of an aortic endograft trial: impact of device failure beyond 12 months. J Vasc Surg. 2001;33:S55-S63.
15. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003;108:1368-1374.
16. Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM, Kooistra T. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:161-167.
17. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J. 2007;28:664-672.
18. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007;34:302-303.
19. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D, Goeddel LA, Hawkins CJ, Thompson RW. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92-101.
20. van der Meij E, Koning GG, Vriens PW, Peeters MF, Meijer CA, Kortekaas KE, Dalman RL, van Bockel JH, Hanemaaijer R, Kooistra T, Kleemann R, Lindeman JH. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One. 2013;8:e53882.
21. Khashram M, Williman JA, Hider PN, Jones GT, Roake JA. Management of modifiable vascular risk factors improves late survival following abdominal aortic aneurysm repair: a systematic review and meta-analysis. Ann Vasc Surg. 2016;22:22.
22. Zhang W, Liu Z, Liu C. Effect of lipid-modifying therapy on long-term mortality after abdominal aortic aneurysm repair: a systemic review and meta-analysis. World J Surg. 2015;39:794-801.
23. Kokje VBC, Hamming JF, Lindeman JHN. Editor’s Choice—pharmaceutical management of small abdominal aortic aneurysms: a systematic review of the clinical evidence. Eur J Vasc Endovasc Surg. 2015;50:702-713.
24. Bardenhagen J, Kausch H, Wenk HH. [Factors with impact on the outcome after surgical interventions for abdominal aortic aneurysms]. Zentralbl Chir. 2015;140:516-524.
25. Dunne JA, Bailey MA, Griffin KJ, Sohrabi S, Coughlin PA, Scott DJ. Statins: the holy grail of abdominal aortic aneurysm (AAA) growth attenuation? A systematic review of the literature. Curr Vasc Pharmacol. 2014;12:168-172.
26. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg. 2012;44:287-292.
27. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev. 2012:CD009536.
28. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg. 2011;98:346-353.
29. Bergqvist D. Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA)—a systematic review. Eur J Vasc Endovasc Surg. 2011;41:663-667.
30. Bailey MA, Dunne JA, Griffin KJ, Coughlin PA, Scott DJ. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms (Br J Surg 2011; 98: 362-353). Br J Surg. 2011;98:744-745; author reply 745.
31. Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg. 2010;52:1675-1681.
32. Guessous I, Periard D, Lorenzetti D, Cornuz J, Ghali WA. The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis. PLoS One. 2008;3:e1895.
33. Sweeting MJ, Thompson SG, Brown LC, Powell JT; RESCAN Collaborators. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg. 2012;99:655-665.
34. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
35. Wells GA, Shea B, O’ Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed January 12, 2017.
36. Mills EJ, O’Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J. 2011;32:1409-1415.
37. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration; 2008. Available at: http://www.cochrane-handbook.org/. Accessed January 12, 2017.
38. Badger SA, Jones C, McClements J, Lau LL, Young IS, Patterson CC. Surveillance strategies according to the rate of growth of small abdominal aortic aneurysms. Vasc Med. 2011;16:415-421.
39. De Martino RR, Beck AW, Hoel AW, Hallett JW, Arya S, Upchurch GR, Cronenwett JL, Goodney PP. Preoperative antiplatelet and statin treatment was not associated with reduced myocardial infarction after high-risk vascular operations in the Vascular Quality Initiative. J Vasc Surg. 2016;63:182-189.e2.
40. Ferguson CD, Clancy P, Bourke B, Walker PJ, Dear A, Buckenham T, Norman P, Golledge J. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010;159:307-313.
41. Galinanes EL, Reynolds S, Dombrovskiy VY, Vogel TR. The impact of preoperative statin therapy on open and endovascular abdominal aortic aneurysm repair outcomes. Vascular. 2015;23:344-349.
42. Gokani VJ, Sidloff D, Bath MF, Bown MJ, Sayers RD, Choke E. A retrospective study: factors associated with the risk of abdominal aortic aneurysm rupture. Vascul Pharmacol. 2015;65-66:13-16.
43. Karlsson L, Bergqvist D, Lindback J, Parsson H. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg. 2009;37:420-424.
44. Karrowni W, Dughman S, Hajj GP, Miller FJ. Statin therapy reduces growth of abdominal aortic aneurysms. J Investig Med. 2011;59:1239-1243.
45. Kertai MD, Boersma E, Westerhout CM, Klein J, van Urk H, Bax JJ, Roelandt JRTC, Poldermans D. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg. 2004;28:343-352.
46. Lederle FA, Noorbaloochi S, Nugent S, Taylor BC, Grill JP, Kohler TR, Cole L. Multicentre study of abdominal aortic aneurysm measurement and enlargement. Br J Surg. 2015;102:1480-1487.
47. Leurs LJ, Visser P, Laheij RJ, Buth J, Harris PL, Blankensteijn JD. Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular. 2006;14:1-8.
48. McNally MM, Agle SC, Parker FM, Bogey WM, Powell CS, Stoner MC. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg. 2010;51:1390-1396.
49. Mosorin M, Niemela E, Heikkinen J, Lahtinen J, Tiozzo V, Satta J, Juvonen T, Biancari F. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg. 2008;7:578-581.
50. Nakayama A, Morita H, Miyata T, Hoshina K, Nagayama M, Takanashi S, Sumiyoshi T, Komuro I, Nagai R. Predictors of mortality after emergency or elective repair of abdominal aortic aneurysm in a Japanese population. Heart Vessels. 2014;29:65-70.
51. O’Donnell TFX, Deery SE, Shean KE, Mittleman MA, Darling JD, Eslami MH, DeMartino RR, Schermerhorn ML. Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair. J Vasc Surg. 2018;68:392-399.
52. Schlosser FJ, Tangelder MJ, Verhagen HJ, van der Heijden GJ, Muhs BE, van der Graaf Y, Moll FL; Smart Study Group. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg. 2008;47:1127-1133.
53. Schouten O, Kok NFM, Hoedt MTC, van Laanen JHH, Poldermans D. The influence of aneurysm size on perioperative cardiac outcome in elective open infrarenal aortic aneurysm repair. J Vasc Surg. 2006;44:435-441.
54. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrun M, Bax JJ, Koning J, van Urk H, Poldermans D. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21-26.
55. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006;97:279-280.
56. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg. 2010;52:1-4.
57. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg. 2010;52:55-61.e2.
58. Wemmelund H, Hogh A, Hundborg HH, Thomsen RW, Johnsen SP, Lindholt JS. Statin use and rupture of abdominal aortic aneurysm. Br J Surg. 2014;101:966-975.
59. Yoshimura K, Nagasawa A, Kudo J, Onoda M, Morikage N, Furutani A, Aoki H, Hamano K. Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue. Int J Mol Sci. 2015;16:11213-11228.
60. Schweitzer M, Mitmaker B, Obrand D, Sheiner N, Abraham C, Dostanic S, Meilleur M, Sugahara T, Chalifour LE. Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc Endovasc Surg. 2010;44:116-122.
61. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg. 2002;36:158-163.
62. Crowther M, Goodall S, Jones JL, Bell PR, Thompson MM. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg. 2000;32:575-583.
63. Crowther M, Goodall S, Jones JL, Bell PR, Thompson MM. Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br J Surg. 2000;87:1391-1400.
64. Newman KM, Jean-Claude J, Li H, Scholes JV, Ogata Y, Nagase H, Tilson MD. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg. 1994;20:814-820.
65. Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapiere CM. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg. 1996;24:127-133.
66. Verschuren L, Lindeman JH, van Bockel JH, Abdul-Hussien H, Kooistra T, Kleemann R. Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal. 2005;7:1195-1202.
67. Nollendorfs A, Greiner TC, Nagase H, Baxter BT. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms. J Vasc Surg. 2001;34:316-322.
68. Szilagyi DE, Smith RF, DeRusso FJ, Elliott JP, Sherrin FW. Contribution of abdominal aortic aneurysmectomy to prolongation of life. Ann Surg. 1966;164:678-699.
69. Reed WW, Hallett JW, Damiano MA, Ballard DJ. Learning from the last ultrasound. A population-based study of patients with abdominal aortic aneurysm. Arch Intern Med. 1997;157:2064-2068.
70. Limet R, Sakalihassan N, Albert A. Determination of the expansion rate and incidence of rupture of abdominal aortic aneurysms. J Vasc Surg. 1991;14:540-548.
71. Guirguis EM, Barber GG. The natural history of abdominal aortic aneurysms. Am J Surg. 1991;162:481-483.
72. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg. 1999;230:289-296; discussion 296-297.
73. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
74. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-2031.
75. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
76. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
77. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35:2864-2872.
78. Vanni V, Turtiainen J, Hakala T, Salenius J, Suominen V, Oksala N, Hernesniemi J. Vascular comorbidities and demographics of patients with ruptured abdominal aortic aneurysms. Surgery. 2016;159:1191-1198.
79. Elkalioubie A, Haulon S, Duhamel A, Rosa M, Rauch A, Staels B, Susen S, Van Belle E, Dupont A. Meta-analysis of abdominal aortic aneurysm in patients with coronary artery disease. Am J Cardiol. 2015;116:1451-1456.
80. Durieux R, Van Damme H, Labropoulos N, Yazici A, Legrand V, Albert A, Defraigne JO, Sakalihasan N. High prevalence of abdominal aortic aneurysm in patients with three-vessel coronary artery disease. Eur J Vasc Endovasc Surg. 2014;47:273-278.
81. Baumgartner I, Hirsch AT, Abola MT, Cacoub PP, Poldermans D, Steg PG, Creager MA, Bhatt DL; REACH Registry Investigators. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Vasc Surg. 2008;48:808-814.
82. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:e71-e126.
83. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Hiratzka LF, Murphy WRC, Puschett JB, Rosenfield KA, Sacks D, Taylor LM, White RA. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:1425-1443.
84. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GB, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32:1263-1282.
85. Kurzencwyg D, Filion KB, Pilote L, Nault P, Platt RW, Rahme E, Steinmetz O, Eisenberg MJ. Cardiac medical therapy among patients undergoing abdominal aortic aneurysm repair. Ann Vasc Surg. 2006;20:569-576.
86. Sharma S, Thapa R, Jeevanantham V, Myers T, Hu C, Brimacombe M, Vacek JL, Dawn B, Gupta K. Comparison of lipid management in patients with coronary versus peripheral arterial disease. Am J Cardiol. 2014;113:1320-1325.
87. Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol. 2017;69:2293-2300.
88. Beales L, Wolstenhulme S, Evans JA, West R, Scott DJ. Reproducibility of ultrasound measurement of the abdominal aorta. Br J Surg. 2011;98:1517-1525.